Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.38 |
| ▸ | CDC7 | O00311 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10315974 | 0.71 | MAPK1 (0.46) | MAPK1CDC7RXRAGRIN1GRIN2B | |
| SCHEMBL10419333 | 0.67 | SLC18A2 (0.43) | TAAR1 | |
| SCHEMBL8277800 | 0.63 | MAOB (0.43) | CDC7TDP1L3MBTL1 | |
| SCHEMBL8279879 | 0.59 | MAOB (0.44) | TAAR1L3MBTL1 | |
| SCHEMBL6461426 | 0.59 | L3MBTL1 (0.48) | TDP1L3MBTL1 | |
| SCHEMBL31341937 | 0.59 | DRD2 (0.41) | — | |
| SCHEMBL7719318 | 0.59 | GRM2 (0.40) | MAPK1TDP1L3MBTL1 | |
| SCHEMBL1563949 | 0.59 | MAOB (0.54) | — | |
| SCHEMBL30346465 | 0.59 | TSHR (0.48) | TDP1L3MBTL1 | |
| SCHEMBL8186168 | 0.58 | L3MBTL1 (0.50) | TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791144-B2 | Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-29 | — | — | US | disclosed |
| US-20120172354-A1 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-05 | — | — | US | disclosed |
| US-20120172354-A1 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-05 | — | — | US | disclosed |
| WO-2011033018-A1 | SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172354-A1 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines | CHRM1, CHRNA1, CHRM3 | MAPK1 1404/4885CDC7 3208/4885RXRA 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.